Prognostic value of circulating CD34+ cells in myelodysplastic syndromes.
We studied circulating (C)CD34(+) cells by flow cytometry in 96 patients with myelodysplastic syndromes (MDS) at diagnosis, and in a subset of 35 cases during follow-up. CCD34(+) counts were stratified within both International Prognostic Scoring System (IPSS) and World Health Organization (WHO) categories. Counts >10/microl were associated with poorer leukemia-free survival, a prognostic value for evolution independent from that of WHO, and a higher progression probability within intermediate-risk IPSS and WHO classes. When serial measurements were performed, counts >10/microl more frequently correlated to evolution. Separating newly diagnosed patients on the basis of 10/microl cut-off of circulating CD34(+) cells retains prognostic utility, especially in intermediate-risk MDS.
Cesana
Clara
C
Department of Transfusion Medicine and Division of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy. clara.cesana@ospedaleniguarda.it
Klersy
Catherine
C
Brando
Bruno
B
Nosari
Annamaria
A
Scarpati
Barbara
B
Scampini
Linda
L
Molteni
Alfredo
A
Nador
Guido
G
Santoleri
Luca
L
Formenti
Marta
M
Valentini
Marina
M
Mazzone
Antonino
A
Morra
Enrica
E
Cairoli
Roberto
R
D000368:Aged; D018952:Antigens, CD34 / Q000097:blood*; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D008297:Male; D009190:Myelodysplastic Syndromes / Q000097:blood*; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
D018952:Antigens, CD34